bibliographicCitation |
Harada KI, Sato R, Bando Y, Sano A, Matsushita Y, Tamura K, Terakawa T, Furukawa J, Fujimoto N, Fujisawa M, Miyake H. Efficacy and safety of pembrolizumab and axitinib as first-line treatment for patients with advanced renal cell carcinoma: Real-world experience in Japan. Int J Urol. 2023 Sep;30(9):772–7. doi: 10.1111/iju.15230. PMID: 37345413. |